Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: lørdag 24. februar
Teknisk analyse
Nyheter
Om BGBIO
Intradagsgraf
Korrelasjoner
Handelslogg
Dybdelogg
Dataeksport
Legg til interesseliste
Handle BGBIO
Sanntidssnapshot
Dato Antall dager Distributør Papir Børs Søk  
Dato Tid Selskap Overskrift
19/02-2018 09:08:00 BGBIO Nyheter løfter flere aksjer (Hegnar)
  08:16:00 BGBIO BergenBio oppdaterer markedet (Hegnar)
  08:00:13 BGBIO BerGenBio har fullført rekruttering av pasienter til første halvdel av Fase II-forsøket med bemcentinib i kombinasjon med KEYTRUDA® i brystkref (OBI)
  08:00:13 BGBIO BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA (OBI)
  08:00:00 BGBIO BerGenBio har fullført rekruttering av pasienter til første halvdel av Fase II-forsøket med bemcentinib i kombinasjon med KEYTRUDA® i brystkreft (Cision)
  08:00:00 BGBIO BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA® (Cision)
16/02-2018 14:43:00 BGBIO BerGenBio-styret tar grep (Hegnar)
  13:50:42 BGBIO BerGenBio ASA: Notice of extraordinary general meeting (OBI)
15/02-2018 12:05:00 TGS SBO BGBIO Anbefaler aksje . advarer mot høy risiko (Hegnar)
  09:25:00 BGBIO Her kunne du doblet pengene dine på få uker (Hegnar)
14/02-2018 10:03:00 BGBIO DNB Markets høyner kursmålet på BergenBio (Hegnar)
13/02-2018 08:00:21 BGBIO BerGenBio ASA: Exercise of employee share options and increase of capital (OBI)
  07:00:27 BGBIO BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017 (OBI)
  07:00:23 BGBIO Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018. (OBI)
  07:00:00 BGBIO Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018. (Cision)
  07:00:00 BGBIO BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017 (Cision)
08/02-2018 13:27:00 BGBIO Her kunne du fått 78 prosent avkastning på seks uker (Hegnar)
07/02-2018 11:28:00 SCH BGBIO Delphi-forvalter slo børsen (Hegnar)
06/02-2018 08:00:22 BGBIO BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast (OBI)
  08:00:00 BGBIO BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast (Cision)
29/01-2018 09:10:00 BGBIO PHLY Oslo Børs åpner opp (Hegnar)
  08:40:00 BGBIO «Oppmuntrende» fra BerGenBio (Hegnar)
  08:00:08 BGBIO BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy (OBI)
  08:00:00 BGBIO BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy (Cision)
25/01-2018 13:50:00 BGBIO Trond Mohn 82 millioner rikere på én dag (Hegnar)
24/01-2018 09:12:00 BGBIO Doblingskandidat tar av i børsåpningen (Hegnar)
  08:22:00 BGBIO Arctic jekker opp BerGenBio (Hegnar)
09/01-2018 08:54:00 BGBIO BerGenBio oppdaterer markedet (Hegnar)
  08:00:10 BGBIO BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 (bemcentinib) in NSCLC (OBI)
  08:00:00 BGBIO BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 (bemcentinib) in NSCLC (Cision)
08/01-2018 08:00:23 BGBIO BerGenBio to present at Biotech Showcase 2018 (OBI)
  08:00:00 BGBIO BerGenBio to present at Biotech Showcase 2018 (Cision)
21/12-2017 11:13:01 BGBIO Financial calendar (OBI)
14/12-2017 11:22:46 BGBIO BerGenBio ASA: Share capital increase (OBI)
  07:00:16 BGBIO BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB's 8th Annual Nordic Healthcare Conference (OBI)
  07:00:00 BGBIO BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB's 8th Annual Nordic Healthcare Conference (Cision)
11/12-2017 07:00:26 BGBIO BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting (OBI)
  07:00:00 BGBIO BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting (Cision)
27/11-2017 09:55:00 BGBIO Hump i veien for BerGenBio (Hegnar)
  08:45:11 BGBIO BerGenBio - US Clinical Trial Update (OBI)
17/11-2017 08:00:21 BGBIO BerGenBio ASA: Exercise of employee share options and increase of capital (OBI)
  07:00:21 BGBIO BerGenBio ASA: Results for the Third Quarter 2017 (OBI)
  07:00:00 BGBIO BerGenBio ASA: Results for the Third Quarter 2017 (Cision)
16/11-2017 11:15:16 BGBIO BerGenBio to present at Jefferies 2017 London Healthcare Conferenc (OBI)
  11:15:00 BGBIO BerGenBio to present at Jefferies 2017 London Healthcare Conference (Cision)
14/11-2017 08:00:11 BGBIO BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposiu (OBI)
  08:00:00 BGBIO BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium (Cision)
10/11-2017 11:00:06 BGBIO BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast (OBI)
  11:00:00 BGBIO BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast (Cision)
01/11-2017 14:29:00 BGBIO BergenBio valgt ut til presentasjon (Hegnar)
Sidestørrelse:
Utforming |  Hjelp |  Utskrift  | Bytt til sanntid Ingen åpne markeder
lørdag 24/02-2018 13:16:25